Search hospitals > Ontario > TORONTO
Sunnybrook Research Institute
Claim this profileTORONTO, Ontario M4N 3M5
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Melanoma
Conducts research for Prostate Cancer
Conducts research for Solid Tumors
92 reported clinical trials
14 medical researchers
Summary
Sunnybrook Research Institute is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Cancer, Melanoma, Prostate Cancer, Solid Tumors and other specialties. Sunnybrook Research Institute is involved with conducting 92 clinical trials across 113 conditions. There are 14 research doctors associated with this hospital, such as Sandra Black, MD, Laurence Klotz, MD, Andrew Loblaw, MD, and Nir Lipsman, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Cancer
Global LeaderStage IV
Stage III
BRAF
Top PIs
Sandra Black, MDSunnybrook Health Sciences Centre5 years of reported clinical research
Studies Alzheimer's Disease
Studies Mild Cognitive Impairment
10 reported clinical trials
21 drugs studied
Laurence Klotz, MDSunnybrook Health Sciences Centre5 years of reported clinical research
Studies Prostate Cancer
Studies Recurrence
8 reported clinical trials
17 drugs studied
Andrew Loblaw, MDSunnybrook Health Sciences Centre6 years of reported clinical research
Studies Prostate Cancer
Studies Recurrence
7 reported clinical trials
9 drugs studied
Nir Lipsman, MDSunnybrook Research Institute4 years of reported clinical research
Studies Brain Tumor
Studies Glioblastoma
7 reported clinical trials
10 drugs studied
Clinical Trials running at Sunnybrook Research Institute
Breast Cancer
Brain Tumor
Ovarian Cancer
Melanoma
Prostate Cancer
Solid Tumors
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Lymphoma
Blood Cancers
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
ARV-471
for Breast Cancer
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sunnybrook Research Institute?
Sunnybrook Research Institute is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Cancer, Melanoma, Prostate Cancer, Solid Tumors and other specialties. Sunnybrook Research Institute is involved with conducting 92 clinical trials across 113 conditions. There are 14 research doctors associated with this hospital, such as Sandra Black, MD, Laurence Klotz, MD, Andrew Loblaw, MD, and Nir Lipsman, MD.